Is Egrifta (Tesamorelin) Legal in Washington State?

HealthRX.com

Egrifta has federal FDA approval; state rules are separate

Print or save as PDF

Key numbers

  • 1.4 mgEgrifta SV daily dose, given by subcutaneous injection into the abdomenSource: accessdata.fda.gov, as cited Nov 7, 2026
  • 1.28 mgEgrifta WR daily dose, given by subcutaneous injection into the abdomenSource: accessdata.fda.gov, as cited Nov 7, 2026
  • 11.6 mgEgrifta WR vial size, a separate product that is not substitutable with Egrifta SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Federal status / FDA-approved prescription product, BLA 022505, first approved November 10, 2010 [1]
  • Current products / Egrifta SV 2 mg vial (1.4 mg daily) and Egrifta WR 11.6 mg vial (1.28 mg daily); not substitutable [2][3]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight loss [2]
  • Boxed warning / None in either current label [2][3]
  • Compounding / Not on FDA's significant-safety-risk list and in no category of FDA's compounding lists [4][5][6]
  • Sport / Prohibited at all times by WADA (S2.2.4) [7][8]

What the federal status is

Tesamorelin is the active ingredient in two FDA-approved prescription products: Egrifta SV (2 mg vial, 1.4 mg injected subcutaneously into the abdomen once daily) and Egrifta WR (11.6 mg vial, 1.28 mg once daily). Both are prescription-only, both labels are dated July 29, 2026, and the labels state the two are not substitutable [1][2][3]. The application, BLA 022505, was first approved on November 10, 2010 [1]. Tesamorelin is a synthetic analog of human growth hormone-releasing factor that binds pituitary GRF receptors and stimulates release of the body's own growth hormone, which raises IGF-1 and IGFBP-3 [2].

Questions worth asking

Choose the questions you want to keep

What the approval covers

The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The label states that long-term cardiovascular safety has not been established, that the risk and benefit of continuing should be weighed in patients who have not had a reduction in visceral adipose tissue, and that it is not indicated for weight loss management because its effect on weight is neutral [2]. Use in people without HIV lipodystrophy falls outside the approved indication [2].

Compounded tesamorelin

Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [9][10]. FDA has made no category-based statement about compounding tesamorelin: it is not on FDA's list of bulk substances that may present significant safety risks (content dated 04/22/2026), and it appears in no category of FDA's lists for state-licensed pharmacies and physicians (updated May 14, 2026) or for outsourcing facilities (updated March 21, 2025) [4][5][6]. It is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding filed October 28, 2026: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [9][10].

Sport

WADA names tesamorelin in section S2.2.4 (growth hormone releasing factors) and prohibits it at all times, in and out of competition; it is on the 2026 Prohibited List, in force since January 1, 2026, and remains on the 2027 List [7][8].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. According to the article, what is the daily dose of Egrifta SV?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is Egrifta (tesamorelin) legal in Washington State?
Egrifta SV and Egrifta WR are FDA-approved prescription products, and that federal status is established [1][2][3]. Washington-specific statutes and pharmacy-board requirements are separate from federal status and are not addressed here.
Does tesamorelin require a prescription?
Yes. Both current products are marketed as prescription drugs. Egrifta SV is dosed at 1.4 mg once daily and Egrifta WR at 1.28 mg once daily, each by subcutaneous injection into the abdomen [1][2][3].
Does the approval cover weight loss or anti-aging use?
No. The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the label says it is not indicated for weight loss and describes its effect on weight as neutral [2]. Use in people without HIV lipodystrophy falls outside the label [2].
Has FDA said anything about compounding tesamorelin?
FDA has made no category-based statement. Tesamorelin is not on its list of bulk drugs that may present significant safety risks and appears in no category of its lists for state-licensed pharmacies, physicians or outsourcing facilities [4][5][6]. It is also not among the six peptides named in the HHS draft enforcement-discretion policy filed October 28, 2026 [9][10].
What are the labeled contraindications?
Disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is it just me or Tesamorlin seems like a waste?

The approved use is narrow. Tesamorelin is approved only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss because its effect on weight is neutral, and use in people without HIV lipodystrophy falls outside the approved indication.

Where to buy tesamorelin peptide reddit?

No place to buy tesamorelin, and no price, is given. Both Egrifta SV and Egrifta WR are prescription-only products, and the two are not substitutable for each other. FDA has made no category-based statement about compounding tesamorelin.

Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. World Anti-Doping Agency.
  8. World Anti-Doping Agency.
  9. Official web page.
  10. Official web page.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Washington State?